Navidea Biopharmaceuticals (NAVB) 10-Q 14 Nov 22 2022 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2022	Nov. 07, 2022
Document Information [Line Items]
Entity Central Index Key	0000810509
Entity Registrant Name	NAVIDEA BIOPHARMACEUTICALS, INC.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2022
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2022
Document Transition Report	false
Entity File Number	001-35076
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	31-1080091
Entity Address, Address Line One	4995 Bradenton Avenue, Suite 240
Entity Address, City or Town	Dublin
Entity Address, State or Province	OH
Entity Address, Postal Zip Code	43017-3552
City Area Code	614
Local Phone Number	793-7500
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		32,364,362
Preferred Stock Purchase Rights [Member]
Document Information [Line Items]
Title of 12(b) Security	Preferred Stock Purchase Rights
Common Stock [Member]
Document Information [Line Items]
Title of 12(b) Security	Common Stock
Trading Symbol	NAVB
Security Exchange Name	NYSEAMER

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 4,600,791	$ 4,230,865
Receivables	155,189	92,992
Inventory, net	193,806	151,155
Prepaid expenses and other	150,125	908,273
Total current assets	5,099,911	5,383,285
Property and equipment	835,845	866,306
Less accumulated depreciation and amortization	686,828	745,816
Property and equipment, net	149,017	120,490
Right-of-use lease assets	448,940	448,940
Less accumulated amortization	412,458	320,725
Right-of-use lease assets, net	36,482	128,215
License agreements, patents and trademarks	1,143,814	953,424
Less accumulated amortization	202,566	167,773
License agreements, patents and trademarks, net	941,248	785,651
Other assets	31,774	227,192
Total assets	6,258,432	6,644,833
Current liabilities:
Accounts payable	1,738,519	1,421,317
Accrued liabilities and other	5,866,992	3,149,340
Note payable, current	0	453,427
Lease liabilities, current	27,346	275,718
Deferred revenue, current	800,000	0
Total current liabilities	8,432,857	5,299,802
Lease liabilities, net of current portion	1,690	20,288
Deferred revenue	700,000	700,000
Note payable to related party, net of discount of $708,999	1,791,001	0
Total liabilities	10,925,548	6,020,090
Commitments and contingencies (See Note 10)
Stockholders’ (deficit) equity:
Common stock; $.001 par value, 300,000,000 shares authorized; 32,150,918 and 30,279,922 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively	223,148	221,277
Additional paid-in capital	379,337,227	370,459,705
Accumulated deficit	(384,520,021)	(370,787,610)
Total stockholders' deficit	(4,959,633)	(106,556)
Noncontrolling interest	292,517	731,299
Total Navidea stockholders’ (deficit) equity	(4,667,116)	624,743
Total liabilities and stockholders’ (deficit) equity	6,258,432	6,644,833
Non-Series Preferred Stock [Member]
Stockholders’ (deficit) equity:
Preferred stock	0	0
Series D Preferred Stock [Member]
Stockholders’ (deficit) equity:
Preferred stock	0	22
Series E Preferred Stock [Member]
Stockholders’ (deficit) equity:
Preferred stock	0	50
Series G Preferred Stock [Member]
Stockholders’ (deficit) equity:
Preferred stock	3	0
Series H Preferred Stock [Member]
Stockholders’ (deficit) equity:
Preferred stock	0	0
Series I Preferred Stock [Member]
Stockholders’ (deficit) equity:
Preferred stock	$ 10	$ 0

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	300,000,000	300,000,000
Common stock, shares issued (in shares)	32,150,918	30,279,922
Common stock, shares outstanding (in shares)	32,150,918	30,279,922
Non-Series Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Series D Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	150,000	150,000
Preferred stock, shares issued (in shares)	0	22,077
Preferred stock, shares outstanding (in shares)	0	22,077
Series E Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	50,000	50,000
Preferred stock, shares issued (in shares)	0	50,000
Preferred stock, shares outstanding (in shares)	0	50,000
Series G Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	3,260	3,260
Preferred stock, shares issued (in shares)	3,260	0
Preferred stock, shares outstanding (in shares)	3,260	0
Series H Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	75,000	75,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Series I Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	35,000	35,000
Preferred stock, shares issued (in shares)	9,667	0
Preferred stock, shares outstanding (in shares)	9,667	0
Note Payable to Related Party [Member]
Note payable to related party, discount	$ 708,999

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)		3 Months Ended		9 Months Ended
		Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenue:
Sales revenue		$ 7,516	$ 9,116	$ 14,035	$ 44,665
Revenue		7,516	9,116	14,035	44,665
Grant and other revenue		0	87,266	51,007	436,500
Total revenue		7,516	96,382	65,042	481,165
Cost of sales		1,432	0	1,905	0
Reserve for expiring inventory		133,006	0	133,006	0
Gross (loss) profit		(126,922)	96,382	(69,869)	481,165
Operating expenses:
Research and development		1,186,419	1,048,786	4,079,661	3,769,596
Selling, general and administrative		3,637,450	1,469,375	6,703,145	5,132,730
Total operating expenses		4,823,869	2,518,161	10,782,806	8,902,326
Loss from operations	[1]	(4,950,791)	(2,421,779)	(10,852,675)	(8,421,161)
Other (expense) income:
Interest expense, net		(765,456)	(2,814)	(852,702)	(4,423)
Gain on extinguishment of debt		0	0	0	366,000
Other, net		8,422	2,800	10,849	(3,141)
Total other (expense) income, net		(757,034)	(14)	(841,853)	358,436
Net loss before income taxes		(5,707,825)	(2,421,793)	(11,694,528)	(8,062,725)
Provision for income taxes		0	(16,043)	0	(16,043)
Net loss		(5,707,825)	(2,437,836)	(11,694,528)	(8,078,768)
Net loss attributable to noncontrolling interest		0	1	4	4
Net loss attributable to Navidea and subsidiaries		(5,707,825)	(2,437,835)	(11,694,524)	(8,078,764)
Deemed dividend on preferred stock exchanged for Units		(2,037,886)	0	(2,037,886)	0
Net loss attributable to common stockholders		$ (7,745,711)	$ (2,437,835)	$ (13,732,410)	$ (8,078,764)
Loss attributable to common stockholders per common share (basic and diluted) (in dollars per share)		$ (0.25)	$ (0.08)	$ (0.45)	$ (0.28)
Weighted average shares outstanding (in shares)		30,732,001	30,122,549	30,404,789	29,067,784
Sales Revenue [Member]
Revenue:
Sales revenue		$ 7,516	$ 0	$ 14,035	$ 0
Revenue		7,516	0	14,035	0
License [Member]
Revenue:
Sales revenue		0	9,116	0	44,665
Revenue		$ 0	$ 9,116	$ 0	$ 44,665
[1]Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments, other than those expenses directly incurred by Navidea Europe, Navidea UK and MT.

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders’ Equity (Unaudited) - USD ($)	Preferred Stock [Member] Series D Preferred Stock [Member]	Preferred Stock [Member] Series E Preferred Stock [Member]	Preferred Stock [Member] Series I Preferred Stock [Member]	Preferred Stock [Member]	Preferred Stock Subscription [Member] Series D Preferred Stock [Member]	Preferred Stock Subscription [Member] Series E Preferred Stock [Member]	Preferred Stock Subscription [Member]	Preferred Stock Subscriptions Receivable [Member] Series D Preferred Stock [Member]	Preferred Stock Subscriptions Receivable [Member] Series E Preferred Stock [Member]	Preferred Stock Subscriptions Receivable [Member]	Common Stock [Member] Series D Preferred Stock [Member]	Common Stock [Member] Series E Preferred Stock [Member]	Common Stock [Member] Series I Preferred Stock [Member]	Common Stock [Member]	Common Stock Subscription [Member] Series D Preferred Stock [Member]	Common Stock Subscription [Member] Series E Preferred Stock [Member]	Common Stock Subscription [Member]	Common Stock Subscriptions Receivable [Member] Series D Preferred Stock [Member]	Common Stock Subscriptions Receivable [Member] Series E Preferred Stock [Member]	Common Stock Subscriptions Receivable [Member]	Additional Paid-in Capital [Member] Series D Preferred Stock [Member]	Additional Paid-in Capital [Member] Series E Preferred Stock [Member]	Additional Paid-in Capital [Member] Series I Preferred Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member] Series D Preferred Stock [Member]	Retained Earnings [Member] Series E Preferred Stock [Member]	Retained Earnings [Member] Series I Preferred Stock [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member] Series D Preferred Stock [Member]	Noncontrolling Interest [Member] Series E Preferred Stock [Member]	Noncontrolling Interest [Member] Series I Preferred Stock [Member]	Noncontrolling Interest [Member]	Series D Preferred Stock [Member]	Series E Preferred Stock [Member]	Series I Preferred Stock [Member]	Total
Balance (in shares) at Dec. 31, 2020				0			132,250							27,149,691			995,000
Balance at Dec. 31, 2020				$ 0			$ 132			$ (10,300,000)				$ 218,146			$ 995			$ (4,975,000)				$ 375,428,014				$ (359,056,683)				$ 731,303				$ 2,046,907
Issued stock to 401(k) plan (in shares)				0			0							30,018			0
Issued stock to 401(k) plan				$ 0			$ 0			0				$ 30			$ 0			0				76,816				0				0				76,846
Stock compensation expense				0			0			0				0			0			0				121,298				0				0				121,298
Net loss				$ 0			0			0				0			0			0				0				(2,966,890)				(2)				(2,966,892)
Issued stock (in shares)	31,750	50,000			(31,750)	0					0	0			0	0
Issued stock	$ 32	$ 50			$ (31)		0	$ 250,000	$ 0					$ 0			0	$ 0	$ 0		$ 0	$ 4,980,659			$ 0	$ 0			$ 0	$ 0			$ 250,001	$ 4,980,709
Issued stock upon conversion (in shares)	(31,750)				0						1,513,978				0
Issued stock upon conversion	$ (32)						$ 0	0			$ 1,514						$ 0	0			(1,482)				0				0				0
Issued restricted stock (in shares)				0			0							12,500			0
Issued restricted stock				$ 0			$ 0			0				$ 13			$ 0			0				0				0				0				13
Issued stock (in shares)	31,750	50,000			(31,750)	0					0	0			0	0
Issued stock	$ 32	$ 50			$ (31)		0	250,000	$ 0					$ 0			0	0	$ 0		0	$ 4,980,659			0	$ 0			0	$ 0			250,001	$ 4,980,709
Issued stock upon conversion	$ (32)						$ 0	0			$ 1,514						$ 0	0			(1,482)				0				0				0
Stock subscribed (in shares)	0				0						0				0
Stock subscribed	$ 0				$ 0			500,000			$ 0				$ 0			0			0				0				0				500,000
Stock subscribed (in shares)	0				0						0				0
Balance (in shares) at Mar. 31, 2021				50,000			100,500							28,706,187			995,000
Balance at Mar. 31, 2021				$ 50			$ 101			(9,550,000)				$ 219,703			$ 995			(4,975,000)				380,605,305				(362,023,573)				731,301				5,008,882
Balance (in shares) at Dec. 31, 2020				0			132,250							27,149,691			995,000
Balance at Dec. 31, 2020				$ 0			$ 132			(10,300,000)				$ 218,146			$ 995			(4,975,000)				375,428,014				(359,056,683)				731,303				$ 2,046,907
Issued stock to 401(k) plan (in shares)																																				30,018
Issued stock to 401(k) plan																																				$ 76,846
Net loss																																				(8,078,768)
Balance (in shares) at Sep. 30, 2021				72,077			0							30,163,245			0
Balance at Sep. 30, 2021				$ 72			$ 0			0				$ 221,160			$ 0			0				370,316,910				(367,135,447)				731,299				4,133,994
Balance (in shares) at Mar. 31, 2021				50,000			100,500							28,706,187			995,000
Balance at Mar. 31, 2021				$ 50			$ 101			(9,550,000)				$ 219,703			$ 995			(4,975,000)				380,605,305				(362,023,573)				731,301				5,008,882
Stock compensation expense				0			0			0				0			0			0				142,180				0				0				142,180
Net loss				$ 0			$ 0			0				$ 0			$ 0			0				0				(2,764,039)				(1)				(2,674,040)
Issued stock (in shares)				23,000			(23,000)							0			0
Issued stock				$ 23			$ (23)			1,800,000				$ 0			$ 0			0				0				0				0				1,800,000
Issued stock upon conversion (in shares)				(23,000)			0							1,437,531			0
Issued stock upon conversion				$ (23)			$ 0			0				$ 1,437			$ 0			0				(1,414)				0				0				0
Issued stock (in shares)				23,000			(23,000)							0			0
Issued stock				$ 23			$ (23)			1,800,000				$ 0			$ 0			0				0				0				0				1,800,000
Issued stock upon conversion				$ (23)			$ 0			0				$ 1,437			$ 0			0				(1,414)				0				0				0
Stock subscribed (in shares)	0			0	55,423		0				0			0	0		(995,000)
Stock subscribed	$ 0			$ 0	$ (56)		$ 0	7,750,000		0	$ 0			$ 0	$ 0		$ (995)	0		4,975,000	(5,542,245)			(4,974,005)	0			0	0			0	2,207,699			0
Stock subscribed (in shares)	0			0	(55,423)		0				0			0	0		995,000
Incurred costs related to Series E Preferred Stock				$ 0			$ 0			0				$ 0			$ 0			0				(50,671)				0				0				(50,671)
Issued stock upon stock option exercise (in shares)				0			0							2,000			0
Issued stock upon stock option exercise				$ 0			$ 0			0				$ 2			$ 0			0				2,118				0				0				2,120
Balance (in shares) at Jun. 30, 2021				50,000			22,077							30,145,718			0
Balance at Jun. 30, 2021				$ 50			$ 22			0				$ 221,142			$ 0			0				370,181,268				(364,697,612)				731,300				6,436,170
Issued stock for payment of director fees (in shares)				0			0							15.027			0
Issued stock for payment of director fees				$ 0			$ 0			0				$ 15			$ 0			0				27,485				0				0				27,500
Stock compensation expense				0			0			0				0			0			0				108,157				0				0				108,157
Net loss				$ 0			$ 0			0				$ 0			$ 0			0				0				(2,437,835)				(1)				(2,437,836)
Issued stock (in shares)	22,077				(22,077)						0				0
Issued stock	$ 22				$ (22)			0			$ 0				$ 0			0			0				0				0				0
Issued restricted stock (in shares)				0			0							2.500			0
Issued restricted stock				$ 0			$ 0			0				$ 3			$ 0			0				0				0				0				3
Issued stock (in shares)	22,077				(22,077)						0				0
Issued stock	$ 22				$ (22)			$ 0			$ 0				$ 0			$ 0			$ 0				$ 0				$ 0				$ 0
Balance (in shares) at Sep. 30, 2021				72,077			0							30,163,245			0
Balance at Sep. 30, 2021				$ 72			$ 0			$ 0				$ 221,160			$ 0			$ 0				370,316,910				(367,135,447)				731,299				4,133,994
Balance (in shares) at Dec. 31, 2021				72,077										30,279,922
Balance at Dec. 31, 2021				$ 72										$ 221,277										370,459,705				(370,787,610)				731,299				624,743
Issued stock in lieu of cash bonuses (in shares)				0										16,632
Issued stock in lieu of cash bonuses				$ 0										$ 17										16,948				0				0				16,965
Issued stock to 401(k) plan (in shares)				0										53,238
Issued stock to 401(k) plan				$ 0										$ 53										44,667				0				0				44,720
Issued stock for payment of director fees (in shares)				0										7,500
Issued stock for payment of director fees				$ 0										$ 7										6,518				0				0				6,525
MT Preferred Stock reacquired due to Platinum settlement				0										0										438,778				0				(438,778)				0
Stock compensation expense				0										0										184,850				0				0				184,850
Net loss				$ 0										$ 0										0				(2,987,242)				(3)				(2,987,245)
Balance (in shares) at Mar. 31, 2022				72,077										30,357,292
Balance at Mar. 31, 2022				$ 72										$ 221,354										371,151,466				(373,774,852)				292,518				(2,109,442)
Balance (in shares) at Dec. 31, 2021				72,077										30,279,922
Balance at Dec. 31, 2021				$ 72										$ 221,277										370,459,705				(370,787,610)				731,299				$ 624,743
Issued stock to 401(k) plan (in shares)																																				53,238
Issued stock to 401(k) plan																																				$ 44,720
Net loss																																				(11,694,528)
Balance (in shares) at Sep. 30, 2022				12,927										32,150,918
Balance at Sep. 30, 2022				$ 13										$ 223,148										379,337,227				(384,520,021)				292,517				(4,667,116)
Balance (in shares) at Mar. 31, 2022				72,077										30,357,292
Balance at Mar. 31, 2022				$ 72										$ 221,354										371,151,466				(373,774,852)				292,518				(2,109,442)
Issued stock for payment of director fees (in shares)				0										7,500
Issued stock for payment of director fees				$ 0										$ 7										6,443				0				0				6,450
Stock compensation expense				0										0										40,554				0				0				40,554
Net loss				$ 0										$ 0										0				(2,999,458)				(1)				(2,999,459)
Series E Preferred Stock exchanged for Series F and Series G Preferred Stock (in shares)				(45,000)										0
Series E Preferred Stock exchanged for Series F and Series G Preferred Stock				$ (45)										$ 0										821,295				0				0				821,250
Balance (in shares) at Jun. 30, 2022				27,077										30,364,792
Balance at Jun. 30, 2022				$ 27										$ 221,361										372,019,758				(376,774,310)				292,517				(4,240,647)
Issued stock in lieu of cash bonuses (in shares)				0										28,150
Issued stock in lieu of cash bonuses				$ 0										$ 28										7,854				0				0				7,882
Issued stock for payment of director fees (in shares)				0										7,500
Issued stock for payment of director fees				$ 0										$ 8										2,942				0				0				2,950
Stock compensation expense				0										0										41,052				0				0				41,052
Net loss				$ 0										$ 0										0				(5,707,825)				0				(5,707,825)
Series E Preferred Stock exchanged for Series F and Series G Preferred Stock (in shares)				(23,817)										0
Series E Preferred Stock exchanged for Series F and Series G Preferred Stock				$ (23)										$ 0										20				0				0				(3)
Issued stock (in shares)			10,423	0									0	70,500
Issued stock			$ 10	$ 0									$ 0	$ 71									$ 5,209,725	19,669			$ 0	0			$ 0	0			$ 5,209,735	19,740
Deemed dividend on Series D and Series F Preferred Stock exchanged for Units in Rights Offering				$ 0																				2,037,886				(2,037,886)				0				0
Issued stock upon conversion (in shares)				(756)										1,679,976
Issued stock upon conversion				$ (1)										$ 1,680										(1,679)				0				0				0
Issued stock (in shares)			10,423	0									0	70,500
Issued stock			$ 10	$ 0									$ 0	$ 71									$ 5,209,725	19,669			$ 0	0			$ 0	0			$ 5,209,735	19,740
Issued stock upon conversion				$ (1)										$ 1,680										(1,679)				0				0				0
Balance (in shares) at Sep. 30, 2022				12,927										32,150,918
Balance at Sep. 30, 2022				$ 13										$ 223,148										$ 379,337,227				$ (384,520,021)				$ 292,517				$ (4,667,116)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities:
Net loss	$ (11,694,528)	$ (8,078,768)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	69,352	55,672
Loss on disposal and abandonment of assets	64,833	19,962
Reserve for expiring inventory	133,006	0
Amortization of debt discount and issuance costs	126,878	0
Non-cash lease expense	91,733	91,456
Stock compensation expense	266,456	371,637
Gain on extinguishment of debt	0	(366,000)
Value of stock issued to 401(k) plan for employer matching contributions	44,720	76,846
Value of stock issued in payment of employee bonuses	24,847	0
Value of stock issued under long term incentive plan	19,740	0
Value of stock issued in payment of director fees	15,925	27,500
Changes in operating assets and liabilities:
Receivables	(62,197)	(46,005)
Inventory	(175,657)	(9,137)
Prepaid expenses and other assets	953,566	507,225
Accounts payable	317,202	44,512
Accrued and other liabilities	2,727,010	35,161
Lease liabilities	(266,970)	(210,434)
Deferred revenue	790,644	(9,356)
Net cash used in operating activities	(6,553,440)	(7,489,729)
Cash flows from investing activities:
Payments for purchases of equipment	(63,086)	(20,749)
Patent and trademark costs	(255,224)	(219,236)
Net cash used in investing activities	(318,310)	(239,985)
Cash flows from financing activities:
Proceeds from issuance of preferred stock and warrants, including collection of stock subscriptions	6,173,000	12,682,700
Proceeds from issuance of common stock	0	2,135
Proceeds from note payable	2,500,000	0
Payment of debt issuance costs	(14,627)	0
Principal payments on notes payable	(453,427)	(379,443)
Net cash provided by financing activities	7,241,676	12,235,430
Net increase in cash and cash equivalents	369,926	4,505,716
Cash and cash equivalents, beginning of period	4,230,865	2,670,495
Cash and cash equivalents, end of period	4,600,791	7,176,211
Preferred Stock Issuance Costs [Member]
Cash flows from financing activities:
Payment of stock issuance costs	$ (963,270)	$ (69,962)

Note 1 - Summary of Significant

Note 1 - Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Significant Accounting Policies [Text Block]	1. Summary of Significant Accounting Policies a. Basis of Presentation: September 30, 2022 three nine September 30, 2022 2021 September 30, 2022 not December 31, 2021, 10 March 28, 2022 ( “2021 10 Our condensed consolidated financial statements include the accounts of Navidea and our wholly owned subsidiaries, Navidea Biopharmaceuticals Europe Limited (“Navidea Europe”) and Navidea Biopharmaceuticals Limited (“Navidea UK”), as well as those of our majority-owned subsidiary, Macrophage Therapeutics, Inc. (“MT”). All significant inter-company accounts were eliminated in consolidation. b. Revenue Recognition: one We also earn revenue from product sales to end customers, primarily in Europe. Revenue from product sales is generally recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation, which occurs upon either shipment of the product or arrival at its destination, depending upon the shipping terms of the transaction. Our customers have no may In addition, we earn revenues related to our licensing and distribution agreements. The consideration we are eligible to receive under our licensing and distribution agreements typically includes upfront payments, reimbursement for research and development (“R&D”) costs, milestone payments, and royalties. Each licensing and distribution agreement is unique and requires separate assessment in accordance with current accounting standards. See Note 3. c Research and Development Costs: d. Inventory: first first 6. e. Intangible Assets: no nine September 30, 2022 2021, nine September 30, 2022 2021, f. Leases: 12 not 9. g. Contingent Liabilities: 450, Contingencies 10 10. h. Recently Adopted Accounting Standards: May 2021, No. 2021 04, Issuer s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options 2021 04 2021 04 2021 04 2021 04 December 15, 2021, 2021 04 not In November 2021, No. 2021 10, Disclosures by Business Entities about Government Assistance 2021 10 2021 10 1 2 3 2021 10 December 15, 2021. 2021 10 1 2 2021 10 not

Note 2 - Liquidity

Note 2 - Liquidity	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	2. Liquidity As disclosed in the notes to the consolidated financial statements included in the Company’s 2021 10 January 2022. The Company is also engaged in ongoing litigation with Capital Royalty Partners II L.P. (“CRG”). On August 30, 2022, August 31, 2022, not September 9, 2022, October 11, 2022, September 30, 2022, 10. On April 10, 2022, July 1, 2022. two second first 8. On August 30, 2022, August 3, 2022 10,423 one may five 3 The Company has previously entered into an API Development Funding and Access Agreement (“API Development Agreement”) with a strategic partner for assistance with the development and supply of the active pharmaceutical ingredient (“API”) used to manufacture Lymphoseek (technetium Tc 99m two August 11, 2022, first not March 31, 2023. July 1, 2023 We do not 19 19 NAV3 32 19 19 The current conflict between Ukraine and Russia has created extreme volatility in the global capital markets and is expected to have further global economic consequences, including disruptions of the global supply chain and energy markets. Any such volatility and disruptions may third may The Company has experienced recurring net losses and has used significant cash to fund its operations. The Company has considerable discretion over the extent of development project expenditures and has the ability to curtail the related cash flows as needed. The Company also continues working to establish new sources of funding, including potential equity and/or debt financings, collaborations and additional grant funding that can augment the balance sheet. However, based on our current working capital and our projected cash burn, management believes that there is substantial doubt about the Company’s ability to continue as a going concern for a period of one 10

Note 3 - Revenue From Contracts

Note 3 - Revenue From Contracts With Customers	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	3. Revenue from Contracts with Customers Navidea is focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. We manage our business based on two Tc99m Tc99m one Tc99 We earn revenue from product sales to end customers, primarily in Europe. Revenue from product sales is generally recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation, which occurs upon either shipment of the product or arrival at its destination, depending upon the shipping terms of the transaction. Our customers have no may 30 90 The Company also recognizes revenue from up-front license fees and pre-market milestones after the cash has been received from its customers and the performance obligations have been met. Payments for sales-based royalties and milestones are generally received after the related revenue has been recognized and invoiced. Normal payment terms generally range from 15 to 90 days following milestone achievement or royalty invoice, in accordance with each contract. Up-front and milestone payments received related to our license and distribution agreements in India and China are deferred until Tc99m Tc99m March 2022, not Tc99m not no not eight ten The transaction price of a contract is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to a customer. Transaction prices do not third not When estimating a contract’s transaction price, the Company considers all the information (historical, current, and forecasted) that is reasonably available to it and identifies possible consideration amounts. Most of the Company’s contracts with customers include both fixed and variable components of the transaction price. Under those contracts, some or all of the consideration for satisfied performance obligations is contingent on events over which the Company has no Tc99m The milestone payments have a binary outcome (that is, the Company will either receive all or none not Royalties are estimated based on the expected value method because they are based on a variable amount of sales representing a range of possible outcomes. However, when taking into account the constraint on variable consideration, the estimate of future royalties included in the transaction price is generally $0. Tc99m not no no Up-front fees, milestones and royalties are generally non-refundable. Therefore, the Company does not During the three September 30, 2022 2021, nine September 30, 2022 2021, three nine September 30, 2022 2021, not The following table disaggregates the Company’s revenue from contracts with customers for the three nine September 30, 2022 2021. Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Sales revenue: Tc99m tilmanocept - Europe $ 7,516 $ — $ 14,035 $ — License revenue: Tc99m tilmanocept - Europe $ — $ 9,116 $ — $ 44,665 The following economic factors affect the nature, amount, timing and uncertainty of the Company’s revenue and cash flows as indicated: Geographical Location of Customers: may may Tc99m Status of Regulatory Approval: Tc99m Tc99m Tc99m March 2022, not Tc99m not may Through September 30, 2022, not The following table summarizes the changes in contract liabilities during the three nine September 30, 2022 2021. Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Total deferred revenue related to contracts with customers, beginning of period $ 700,000 $ 700,000 $ 700,000 $ 700,000 Deferred revenue related to milestones achieved — — 100,000 — Deferred revenue related to milestones achieved, written off due to contract renegotiations — — (100,000 ) — Total deferred revenue related to contracts with customers, end of period $ 700,000 $ 700,000 $ 700,000 $ 700,000 The Company had sales revenue receivable of $7,516 and $0 outstanding as of September 30, 2022 December 31, 2021, September 30, 2022 December 31, 2021, In addition to revenue from contracts from customers, we also generate revenue from National Institutes of Health (“NIH”) grants to support various product development initiatives. The revenue recognition standard applies to revenue from contracts with customers. A customer is defined as a party that has contracted with an entity to obtain goods or services that are an output of the entity’s ongoing major or central operations in exchange for consideration. The Company’s ongoing major or central operations consist of the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The NIH and its various institutes are responsible for biomedical and public health research and provide major biomedical research funding to non-NIH research facilities and entities such as Navidea. While the Company will directly benefit from any knowledge gained from the project, there is also a public health benefit provided, which justifies the use of public funds in the form of the grants. Based on the nature of the Company’s operations and the terms of the grant awards, Navidea does not not three September 30, 2022 2021, nine September 30, 2022 2021,

Note 4 - Stock-based Compensati

Note 4 - Stock-based Compensation	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	4. Stock-Based Compensation For the three September 30, 2022 2021, nine September 30, 2022 2021, not three nine September 30, 2022 2021. A summary of the status of our stock options as of September 30, 2022, nine Nine Months Ended September 30, 2022 Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in years) Aggregate Intrinsic Value Outstanding, January 1, 2022 919,790 $ 5.67 6.5 $ — Granted 12,500 0.83 Cancelled/Forfeited (152,455 ) 2.38 Expired (73,755 ) 22.96 Outstanding, September 30, 2022 706,080 $ 4.48 5.7 $ — Exercisable, September 30, 2022 532,749 $ 5.45 4.7 $ — The weighted average grant date fair value per stock option granted during the nine September 30, 2022 nine September 30, 2022 A summary of the status of our unvested restricted stock as of September 30, 2022, nine Nine Months Ended September 30, 2022 Number of Shares Weighted Average Grant-Date Fair Value Unvested, January 1, 2022 95,000 $ 1.40 Vested (5,000 ) 1.96 Unvested, September 30, 2022 90,000 $ 1.37 As of September 30, 2022,

Note 5 - Loss Per Share

Note 5 - Loss Per Share	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Earnings Per Share [Text Block]	5. Loss Per Share Basic loss per share is calculated by dividing net loss attributable to common stockholders by the weighted-average number of common shares. Diluted loss per share reflects additional common shares that would have been outstanding if dilutive potential common shares had been issued. Potential common shares that may Diluted loss per common share for the nine September 30, 2022 2021 The Company’s unvested restricted stock awards contain nonforfeitable rights to dividends or dividend equivalents, whether paid or unpaid (referred to as “participating securities”). Therefore, the unvested restricted stock awards are required to be included in the number of shares outstanding for both basic and diluted earnings per share calculations. However, due to our loss from continuing operations, 90,000 and 38,333 shares of unvested restricted stock for the nine September 30, 2022 2021,

Note 6 - Inventory

Note 6 - Inventory	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Inventory Disclosure [Text Block]	6. Inventory, Net The components of inventory, net as of September 30, 2022 December 31, 2021 September 30, 2022 December 31, 2021 Materials $ 193,806 $ 50,000 Finished goods 133,006 101,155 Reserve for obsolete finished goods (133,006 ) — Total inventory, net $ 193,806 $ 151,155 During the nine September 30, 2022, nine September 30, 2021. During the three September 30, 2022 2021, nine September 30, 2022 2021,

Note 7 - Accounts Payable, Accr

Note 7 - Accounts Payable, Accrued Liabilities and Other	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]	7. Accounts Payable, Accrued Liabilities and Other Accounts payable as of September 30, 2022 December 31, 2021 September 30, 2022 December 31, 2021 The Company pays director fees in both cash and stock. As a result, the cash portion of director fees due are included in accounts payable and the stock portion are included in accrued liabilities and other in the condensed consolidated balance sheet as of September 30, 2022 December 31, 2021. Under our license agreements with the University of California, San Diego (“UCSD”), we have exclusive world-wide rights to all diagnostic and therapeutic uses of tilmanocept, other than Tc99m September 30, 2022, not

Note 8 - Notes Payable

Note 8 - Notes Payable	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Debt Disclosure [Text Block]	8. Notes Payable Bridge Note from John K. Scott, Jr. On April 10, 2022, July 1, 2022. two second first 11. As consideration and partial inducement for Mr. Scott to enter into the Bridge Note, the Company exchanged all 50,000 shares of Mr. Scott’s Series E Redeemable Convertible Preferred Stock (“Series E Preferred Stock”) for 1,740 shares of Series F Preferred Stock and 3,260 shares of Series G Redeemable Preferred Stock (“Series G Preferred Stock”). In accordance with current accounting guidance, the Company recorded a debt discount of $835,876 including $821,250 related to the difference in the value of Mr. Scott’s Series E Preferred Stock and the Series F and Series G Preferred Stock and $14,626 of debt issuance costs. The debt discount is being amortized as non-cash interest expense using the effective interest method over the term of the Bridge Note. The balance of the debt discount was $708,999 as of September 30, 2022. Interest expense related to the Bridge Note totaled $100,696 and $183,878 during the three nine September 30, 2022, September 30, 2022. IPFS Corporation In November 2020, seven June 2021. November 2021, five April 2022. Interest expense related to the IPFS notes payable totaled $0 during the three September 30, 2022 2021. nine September 30, 2022 2021, September 30, 2022. Summary During the three September 30, 2022 2021, nine September 30, 2022 2021,

Note 9 - Leases

Note 9 - Leases	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	9. Leases We currently lease approximately 5,000 square feet of office space at 4995 June 2023. In addition, we leased approximately 25,000 square feet of office space at 5600 2022. October 2022 five not June 2017, October 2022. We currently lease office equipment at a monthly payment of $136, expiring in October 2024. September 2021. Total operating lease expense was $(29,681) and $41,653 for the three September 30, 2022 2021, nine September 30, 2022 2021, three nine September 30, 2022 one The following table presents information about the amount, timing and uncertainty of cash flows arising from the Company’s operating leases as of September 30, 2022. Maturity of Lease Liabilities Operating Lease Payments 2022 (remaining) $ 9,443 2023 19,699 2024 1,355 Total undiscounted operating lease payments 30,497 Less imputed interest 1,461 Present value of operating lease liabilities $ 29,036 Balance Sheet Classification Current lease liabilities $ 27,346 Noncurrent lease liabilities 1,690 Total operating lease liabilities $ 29,036 Other Information Weighted-average remaining lease term for operating leases (in years) 0.9 Weighted-average discount rate for operating leases 10.7 % Cash paid for amounts included in the present value of operating lease liabilities was $281,668 and $250,376 during the nine September 30, 2022 2021,

Note 10 - Commitments and Conti

Note 10 - Commitments and Contingencies	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	10. Commitments and Contingencies We are subject to legal proceedings and claims that arise in the ordinary course of business. In accordance with ASC Topic 450, Contingencies not CRG Litigation As disclosed in the notes to the financial statements included in the Company’s Annual Report on Form 10 April 2018, not On November 21, 2021, not not August 30, 2022, August 31, 2022, not September 9, 2022 October 11, 2022, September 30, 2022, The Company had also been engaged in ongoing litigation with CRG in the Court of Common Pleas of Franklin County, Ohio (the “Ohio Court”) related to Navidea’s claims that the CRG Lenders fraudulently induced Navidea to enter into a settlement agreement and breached the terms of the same through certain actions taken by the CRG Lenders in connection with the GSA, pursuant to which Navidea agreed to pay up to $66.0 $66.0 $4.1 June 2016 $66.0 $66.0 $7.1 414 May 7, 2019, June 28, 2019. November 27, 2019, $66.0 April 9, 2018, 414 no December 5, 2019, 10th March 27, 2020, September 23, 2020. March 16, 2021, 10th November 27, 2019 not not Platinum Litigation In November 2017, March 3, 2017, October 31, 2018, no On November 30, 2018, January 22, 2019, September 5, 2019. November 25, 2019, not June 4, 2020, September 2, 2020, September 23, 2020 June 28, 2021. January 2022, 11. Goldberg Agreement and Litigation In August 2018, 1,175,000 November 2018, On February 11, 2019, February 19, 2019, March 1, 2019, February 20, 2019, may February 17, 2022, New York Litigation Involving Dr. Goldberg On February 20, 2019, April 26, 2019, June 13, 2019, third On December 26, 2019, third not The District Court also rejected Dr. Goldberg’s claim for wrongful termination as Chief Executive Officer of MT. In addition, the District Court found that Dr. Goldberg lacked standing to seek injunctive relief to force the removal of Dr. Claudine Bruck and Michael Rice from MT’s Board of Directors, to invalidate all actions taken by the MT Board on or after November 29, 2018 ( In addition, the District Court found Navidea’s breach of fiduciary duty claim against Dr. Goldberg for conduct occurring more than three On January 31, 2020, April 1, 2020, On January 27, 2020, July 9, 2020, 1 2 3 4 On August 24, 2020, not third not On May 27, 2021, 1 2 3 not 4 not third 5 6 not On August 6, 2021, June 23, 2021 ( October 14, 2021, March 7, 2022, September 1, 2020. April 8, 2022, September 1, 2020 March 31, 2022. Fact discovery and expert discovery in the New York Action have been completed. The Company has moved to disqualify Dr. Goldberg’s damages expert and briefing in the District Court was submitted on April 1, 2022. November 9, 2022, two November 18, 2022. Delaware Litigation Involving Dr. Goldberg On February 20, 2019, June 12, 2019, not May 23, 2019 On June 23, 2021, not not December 9, 2021, NYSE American Continued Listing Standards On January 28, 2022, not $6.0 1003 February 28, 2022 July 28, 2023. On April 8, 2022, not 1003 1003 $2.0 two three $4.0 three four December 31, 2021 five December 31, 2021. The NYSE American has granted the Company a plan period through July 28, 2023 1003 not not may

Note 11 - Equity

Note 11 - Equity	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	11. Equity Platinum Settlement As discussed in Note 10, January 2022. six Series E Preferred Stock On January 31, 2022, March 2, 2021, six NOL Rights Agreement On April 7, 2022, 382 December 31, 2021, Under the NOL Rights Agreement, the Board declared a non-taxable dividend of one one one may five not The rights issued under the NOL Rights Agreement will expire on the earliest of (i) April 6, 2025; ( 382 no first no may 2022 not Stock Exchange and Loan Agreement On April 10, 2022, two second first As consideration and a partial inducement for Mr. Scott to make the loan, at the closing, Mr. Scott delivered 50,000 shares of Series E Preferred Stock, representing 100% may may not 33.33% 33.33% April 12, 2022. In connection with the Purchase Agreement, the Company entered into a Registration Rights Agreement with Mr. Scott, pursuant to which the Company agreed to file a registration statement with the SEC to register the resale of the shares issuable to Mr. Scott upon conversion of the Series F Preferred Stock. Rights Offering On August 30, 2022, August 3, 2022 one may Both the Series I Preferred Stock and the Warrants are standalone instruments and each is classified as stockholders’ equity. We measured the fair value of the Series I Preferred Stock based on the market price of the underlying Common Stock on the closing date of the Rights Offering. We measured the fair value of the Warrants using the Black-Scholes option pricing model as of the closing date of the Rights Offering. The assumptions used to calculate fair value of the Warrants included volatility of 89.25%, a risk-free rate of 3.27% and expected dividends of $0. We then allocated the total value of the Units sold in the Rights Offering based on the relative fair value of the Series I Preferred Stock and the Warrants. Of the $10,423,000 total value of Units sold in the Rights Offering, we allocated $6,278,815 to the Series I Preferred Stock and $4,144,185 to the Warrants. Certain participants in the Rights Offering had the ability to pay the subscription price for their Units by cancelling or exchanging their shares of Series D Preferred Stock, Series F Preferred Stock and/or Series G Preferred Stock and the Company’s indebtedness evidenced by the Bridge Note, instead of paying by check or wire transfer of funds. The fair market value of the shares of each series of preferred stock and the Bridge Note to be cancelled or exchanged in the Rights Offering was determined by the Company’s Board of Directors with the assistance of an independent appraisal obtained by the Company. In order to help maximize Navidea’s ability to use its NOLs and other tax benefits in future years, Navidea’s Board of Directors exercised its discretion to limit the number of Units that John K. Scott, Jr. could purchase to 2,400 Units, which Mr. Scott elected to pay for by exchanging and surrendering all of his shares of Series F Preferred Stock. Of the total 10,423 Units sold in the Rights Offering, 4,250 Units were sold pursuant to the exchange and surrender of all outstanding shares of Navidea’s Series D Preferred Stock and Series F Preferred Stock. Neither the Series G Preferred Stock nor the Bridge Note was exchanged or cancelled pursuant to the Rights Offering. In accordance with U.S. GAAP, we determined that the fair value of the Series D Preferred Stock and Series F Preferred Stock that was surrendered pursuant to the Rights Offering was approximately $2,212,114. The total fair value of the Units that were issued in exchange for the Series D Preferred Stock and Series F Preferred Stock was $4,250,000. Therefore, the incremental fair value received by the holders of the Series D Preferred Stock and Series F Preferred Stock was approximately $2,037,886. The incremental amount was recognized as a deemed dividend in the Company’s condensed consolidated statement of operations during the third 2022. Net proceeds after deducting fees and expenses of $963,270 related to the Rights Offering will be used to fund our pivotal Phase 3 401 During the nine September 30, 2022 2021, 401 Bonuses Paid in Stock During the nine September 30, 2022, 2021 Long Term Incentive Plan On September 9, 2022, 2014 “2014 3 NAV3 33 Although the Company did not nine September 30, 2022, 2022 2014 2014

Note 12 - Stock Warrants

Note 12 - Stock Warrants	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Stock Warrants Disclosure [Text Block]	12. Stock Warrants On March 3, 2022, On August 30, 2022, five As of September 30, 2022,

Note 13 - Income Taxes

Note 13 - Income Taxes	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Income Tax Disclosure [Text Block]	13. Income Taxes Income taxes are accounted for under the asset and liability method in accordance with Accounting Standards Codification 740, Income Taxes Current accounting standards require a valuation allowance against DTAs if, based on the weight of available evidence, it is more likely than not may not September 30, 2022 December 31, 2021. In assessing the realizability of DTAs, management considers whether it is more likely than not not not not September 30, 2022. Current accounting standards include guidance on the accounting for uncertainty in income taxes recognized in the financial statements. Such standards also prescribe a recognition threshold and measurement model for the financial statement recognition of a tax position taken, or expected to be taken, and provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. The Company believes that the ultimate deductibility of all tax positions is highly certain, although there is uncertainty about the timing of such deductibility. As a result, no liability for uncertain tax positions was recorded as of September 30, 2022 December 31, 2021 not twelve September 30, 2022, 2018 2021 As of September 30, 2022, 2022 2037.

Note 14 - Segments

Note 14 - Segments	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	14. Segments We report information about our operating segments using the “management approach” in accordance with current accounting standards. This information is based on the way management organizes and reports the segments within the enterprise for making operating decisions and assessing performance. Our reportable segments are identified based on differences in products, services and markets served. There were no inter-segment sales. We manage our business based on two Tc99m The information in the following tables is derived directly from each reportable segment’s financial reporting. Three Months Ended September 30, 2022 Diagnostics Therapeutics Corporate Total Sales revenue: United States $ — $ — $ — $ — International 7,516 — — 7,516 Grant and other revenue — — — — Total revenue 7,516 — — 7,516 Cost of revenue, excluding depreciation and amortization 1,432 — — 1,432 Reserve for expiring inventory 133,006 — — 133,006 Research and development expenses 1,073,950 112,469 — 1,186,419 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 745 3,612,002 3,612,747 Depreciation and amortization (2) 8,532 — 16,171 24,703 Income (loss) from operations (3) (1,209,404 ) (113,214 ) (3,628,173 ) (4,950,791 ) Other expense, net (4) — — (757,034 ) (757,034 ) Net loss (1,209,404 ) (113,214 ) (4,385,207 ) (5,707,825 ) Total assets, net of depreciation and amortization: United States $ 50,000 $ — $ 5,929,692 $ 5,979,692 International 271,939 — 6,801 278,740 Capital expenditures 14,429 — — 14,429 Three Months Ended September 30, 2021 Diagnostics Therapeutics Corporate Total License revenue $ 9,116 $ — $ — $ 9,116 Grant and other revenue 87,266 — — 87,266 Total revenue 96,382 — — 96,382 Research and development expenses 906,677 142,109 — 1,048,786 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 744 1,450,565 1,451,309 Depreciation and amortization (2) 6,040 — 12,026 18,066 Loss from operations (3) (816,335 ) (142,853 ) (1,462,591 ) (2,421,779 ) Other expense, net (4) — — (14 ) (14 ) Income tax expense (5,763 ) (824 ) (9,457 ) (16,043 ) Net loss (822,098 ) (143,677 ) (1,472,062 ) (2,437,836 ) Total assets, net of depreciation and amortization: United States $ 185,205 $ — $ 8,557,398 $ 8,742,603 International 216,353 — 590 216,943 Capital expenditures — — 18,042 18,042 Nine Months Ended September 30, 2022 Diagnostics Therapeutics Corporate Total Sales revenue: United States $ — $ — $ — $ — International 14,035 — — 14,035 Grant and other revenue 51,007 — — 51,007 Total revenue 65,042 — — 65,042 Cost of revenue, excluding depreciation and amortization 1,905 — — 1,905 Reserve for expiring inventory 133,006 — — 133,006 Research and development expenses 3,700,528 379,133 — 4,079,661 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 3,746 6,630,047 6,633,793 Depreciation and amortization (2) 20,613 — 48,739 69,352 Loss from operations (3) (3,791,010 ) (382,879 ) (6,678,786 ) (10,852,675 ) Other expense, net (4) — — (841,853 ) (841,853 ) Net loss (3,791,010 ) (382,879 ) (7,520,639 ) (11,694,528 ) Total assets, net of depreciation and amortization: United States $ 50,000 $ — $ 5,929,692 $ 5,979,692 International 271,939 — 6,801 278,740 Capital expenditures 54,650 — 8,436 63,086 Nine Months Ended September 30, 2021 Diagnostics Therapeutics Corporate Total License revenue $ 44,665 $ — $ — $ 44,665 Grant and other revenue 436,500 — — 436,500 Total revenue 481,165 — — 481,165 Research and development expenses 3,359,190 410,406 — 3,769,596 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 3,623 5,073,435 5,077,058 Depreciation and amortization (2) 18,121 — 37,551 55,672 Loss from operations (3) (2,896,146 ) (414,029 ) (5,110,986 ) (8,421,161 ) Other income, net (4) — — 358,436 358,436 Income tax expense (5,763 ) (824 ) (9,457 ) (16,043 ) Net loss (2,901,909 ) (414,853 ) (4,762,007 ) (8,078,768 ) Total assets, net of depreciation and amortization: United States $ 185,205 $ — $ 8,557,398 $ 8,742,603 International 216,353 — 590 216,943 Capital expenditures — — 20,749 20,749 ( 1 General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not ( 2 Depreciation and amortization are reflected in selling, general and administrative expenses ($24,703 and $18,066 for the three September 30, 2022 2021, nine September 30, 2022 2021, ( 3 Loss from operations does not ( 4 Amounts consist primarily of interest income and interest expense, which are not

Note 15 - Supplemental Disclosu

Note 15 - Supplemental Disclosure for Statements of Cash Flows	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Cash Flow, Supplemental Disclosures [Text Block]	15. Supplemental Disclosure for Statements of Cash Flows During the nine September 30, 2022 2021, nine September 30, 2021, 10 December 31, 2020 December 31, 2020. nine September 30, 2022 2021, 401 nine September 30, 2022, 2021 nine September 30, 2022,

Note 16 - Subsequent Events

Note 16 - Subsequent Events	9 Months Ended
	Sep. 30, 2022
Notes to Financial Statements
Subsequent Events [Text Block]	16. Subsequent Events The Company has evaluated events and transactions subsequent to September 30, 2022 10

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Inventory, Policy [Policy Text Block]	d. Inventory: first first 6. e. Intangible Assets: no nine September 30, 2022 2021, nine September 30, 2022 2021, f. Leases: 12 not 9. g. Contingent Liabilities: 450, Contingencies 10 10. h. Recently Adopted Accounting Standards: May 2021, No. 2021 04, Issuer s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options 2021 04 2021 04 2021 04 2021 04 December 15, 2021, 2021 04 not In November 2021, No. 2021 10, Disclosures by Business Entities about Government Assistance 2021 10 2021 10 1 2 3 2021 10 December 15, 2021. 2021 10 1 2 2021 10 not

Note 3 - Revenue From Contrac_2

Note 3 - Revenue From Contracts With Customers (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Sales revenue: Tc99m tilmanocept - Europe $ 7,516 $ — $ 14,035 $ — License revenue: Tc99m tilmanocept - Europe $ — $ 9,116 $ — $ 44,665
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Total deferred revenue related to contracts with customers, beginning of period $ 700,000 $ 700,000 $ 700,000 $ 700,000 Deferred revenue related to milestones achieved — — 100,000 — Deferred revenue related to milestones achieved, written off due to contract renegotiations — — (100,000 ) — Total deferred revenue related to contracts with customers, end of period $ 700,000 $ 700,000 $ 700,000 $ 700,000

Note 4 - Stock-based Compensa_2

Note 4 - Stock-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Nine Months Ended September 30, 2022 Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in years) Aggregate Intrinsic Value Outstanding, January 1, 2022 919,790 $ 5.67 6.5 $ — Granted 12,500 0.83 Cancelled/Forfeited (152,455 ) 2.38 Expired (73,755 ) 22.96 Outstanding, September 30, 2022 706,080 $ 4.48 5.7 $ — Exercisable, September 30, 2022 532,749 $ 5.45 4.7 $ —
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	Nine Months Ended September 30, 2022 Number of Shares Weighted Average Grant-Date Fair Value Unvested, January 1, 2022 95,000 $ 1.40 Vested (5,000 ) 1.96 Unvested, September 30, 2022 90,000 $ 1.37

Note 6 - Inventory (Tables)

Note 6 - Inventory (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Schedule of Inventory, Current [Table Text Block]	September 30, 2022 December 31, 2021 Materials $ 193,806 $ 50,000 Finished goods 133,006 101,155 Reserve for obsolete finished goods (133,006 ) — Total inventory, net $ 193,806 $ 151,155

Note 9 - Leases (Tables)

Note 9 - Leases (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Maturity of Lease Liabilities Operating Lease Payments 2022 (remaining) $ 9,443 2023 19,699 2024 1,355 Total undiscounted operating lease payments 30,497 Less imputed interest 1,461 Present value of operating lease liabilities $ 29,036
Lessee, Operating Lease, Assets and Liabilities [Table Text Block]	Balance Sheet Classification Current lease liabilities $ 27,346 Noncurrent lease liabilities 1,690 Total operating lease liabilities $ 29,036
Lessee, Leases, Other Information [Table Text Block]	Other Information Weighted-average remaining lease term for operating leases (in years) 0.9 Weighted-average discount rate for operating leases 10.7 %

Note 14 - Segments (Tables)

Note 14 - Segments (Tables)	9 Months Ended
	Sep. 30, 2022
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Three Months Ended September 30, 2022 Diagnostics Therapeutics Corporate Total Sales revenue: United States $ — $ — $ — $ — International 7,516 — — 7,516 Grant and other revenue — — — — Total revenue 7,516 — — 7,516 Cost of revenue, excluding depreciation and amortization 1,432 — — 1,432 Reserve for expiring inventory 133,006 — — 133,006 Research and development expenses 1,073,950 112,469 — 1,186,419 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 745 3,612,002 3,612,747 Depreciation and amortization (2) 8,532 — 16,171 24,703 Income (loss) from operations (3) (1,209,404 ) (113,214 ) (3,628,173 ) (4,950,791 ) Other expense, net (4) — — (757,034 ) (757,034 ) Net loss (1,209,404 ) (113,214 ) (4,385,207 ) (5,707,825 ) Total assets, net of depreciation and amortization: United States $ 50,000 $ — $ 5,929,692 $ 5,979,692 International 271,939 — 6,801 278,740 Capital expenditures 14,429 — — 14,429 Three Months Ended September 30, 2021 Diagnostics Therapeutics Corporate Total License revenue $ 9,116 $ — $ — $ 9,116 Grant and other revenue 87,266 — — 87,266 Total revenue 96,382 — — 96,382 Research and development expenses 906,677 142,109 — 1,048,786 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 744 1,450,565 1,451,309 Depreciation and amortization (2) 6,040 — 12,026 18,066 Loss from operations (3) (816,335 ) (142,853 ) (1,462,591 ) (2,421,779 ) Other expense, net (4) — — (14 ) (14 ) Income tax expense (5,763 ) (824 ) (9,457 ) (16,043 ) Net loss (822,098 ) (143,677 ) (1,472,062 ) (2,437,836 ) Total assets, net of depreciation and amortization: United States $ 185,205 $ — $ 8,557,398 $ 8,742,603 International 216,353 — 590 216,943 Capital expenditures — — 18,042 18,042 Nine Months Ended September 30, 2022 Diagnostics Therapeutics Corporate Total Sales revenue: United States $ — $ — $ — $ — International 14,035 — — 14,035 Grant and other revenue 51,007 — — 51,007 Total revenue 65,042 — — 65,042 Cost of revenue, excluding depreciation and amortization 1,905 — — 1,905 Reserve for expiring inventory 133,006 — — 133,006 Research and development expenses 3,700,528 379,133 — 4,079,661 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 3,746 6,630,047 6,633,793 Depreciation and amortization (2) 20,613 — 48,739 69,352 Loss from operations (3) (3,791,010 ) (382,879 ) (6,678,786 ) (10,852,675 ) Other expense, net (4) — — (841,853 ) (841,853 ) Net loss (3,791,010 ) (382,879 ) (7,520,639 ) (11,694,528 ) Total assets, net of depreciation and amortization: United States $ 50,000 $ — $ 5,929,692 $ 5,979,692 International 271,939 — 6,801 278,740 Capital expenditures 54,650 — 8,436 63,086 Nine Months Ended September 30, 2021 Diagnostics Therapeutics Corporate Total License revenue $ 44,665 $ — $ — $ 44,665 Grant and other revenue 436,500 — — 436,500 Total revenue 481,165 — — 481,165 Research and development expenses 3,359,190 410,406 — 3,769,596 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 3,623 5,073,435 5,077,058 Depreciation and amortization (2) 18,121 — 37,551 55,672 Loss from operations (3) (2,896,146 ) (414,029 ) (5,110,986 ) (8,421,161 ) Other income, net (4) — — 358,436 358,436 Income tax expense (5,763 ) (824 ) (9,457 ) (16,043 ) Net loss (2,901,909 ) (414,853 ) (4,762,007 ) (8,078,768 ) Total assets, net of depreciation and amortization: United States $ 185,205 $ — $ 8,557,398 $ 8,742,603 International 216,353 — 590 216,943 Capital expenditures — — 20,749 20,749

Note 1 - Summary of Significa_2

Note 1 - Summary of Significant Accounting Policies (Details Textual) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Patent and Trademark Costs	$ 255,224	$ 219,236
Previously Capitalized Patent Costs Abandoned	$ 64,833	$ 19,874
Minimum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	5 years
Maximum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	15 years

Note 2 - Liquidity (Details Tex

Note 2 - Liquidity (Details Textual) - USD ($)	Aug. 30, 2022	Aug. 11, 2022	Aug. 03, 2022	Jul. 01, 2022	Apr. 12, 2022	Oct. 11, 2022	Sep. 30, 2022	Apr. 10, 2022
Rights Offering, Shares Authorized (in shares)			35,000
Shares Issued, Price Per Share (in dollars per share)			$ 1,000
Units Issued During Period, Units, New Issues (in shares)	10,423
Proceeds from Issuance or Sale of Equity, Total	$ 6,173,000
Class of Warrant or Right, Outstanding (in shares)							23,582,230
Payments to Fund Clinical Research Trial	963,270
Payments of Stock Issuance Costs	$ 963,270
API Development Funding and Access Agreement [Member]
Development Agreement, Reimbursement Amount							$ 1,850,000
Development Agreement, Reimbursement Proceeds		$ 800,000
Unit Warrants [Member]
Class of Warrant or Right, Outstanding (in shares)	1
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	2,222
Class of Warrant or Right, Purchase Price of Stock (in dollars per share)	$ 0.45
Class of Warrants or Rights, Warrant Proceeds if Exercised	$ 11,600,000
Warrants and Rights Outstanding, Term (Year)	5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.50
Series I Preferred Stock [Member]
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)	2,222
Units Sold in Exchange for Series D Preferred Stock [Member]
Units Issued During Period, Units, New Issues (in shares)	4,250
Purchase Agreement [Member] | Vice Chairman of Board of Directors [Member]
Debt Instrument, Face Amount								$ 2,500,000
Proceeds from Issuance of Long-Term Debt, Total				$ 1,000,000	$ 1,500,000
Debt Instrument, Interest Rate, Stated Percentage								8%
CRG Loan Agreement, Texas Case [Member]
Litigation Settlement, Amount Awarded to Other Party	$ 2,600,000
Loss Contingency Accrual, Ending Balance							$ 3,300,000
CRG Loan Agreement, Texas Case [Member] | Subsequent Event [Member]
Loss Contingencies, Interest Rate						18%

Note 3 - Revenue From Contrac_3

Note 3 - Revenue From Contracts With Customers (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Contract with Customer, Payment Term, Minimum (Day)			15 days
Contract with Customer, Payment Term, Maximum (Day)			90 days
Contract with Customer, Transaction Price of Royalties Using Expected Value Method	$ 0		$ 0
Revenue from Contract with Customer, Including Assessed Tax	7,516	$ 9,116	14,035	$ 44,665
Contract with Customer, Asset, Impairment Loss	0	0	0	0
Sales Revenue [Member]
Revenue from Contract with Customer, Including Assessed Tax	7,516	0	14,035	0
Contract with Customer, Asset, after Allowance for Credit Loss, Total	7,516		7,516		$ 0
License [Member]
Revenue from Contract with Customer, Including Assessed Tax	0	9,116	0	44,665
Contract with Customer, Asset, after Allowance for Credit Loss, Total	0		0		$ 1,021
Grant [Member]
Revenue Not from Contract with Customer	$ 0	$ 12,266	$ 51,007	$ 86,500
INDIA
Contract with Customer, Term of Contract (Year)			8 years
CHINA
Contract with Customer, Term of Contract (Year)			10 years

Note 3 - Revenue From Contrac_4

Note 3 - Revenue From Contracts With Customers - Disaggregation of Revenue (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Sales revenue	$ 7,516	$ 9,116	$ 14,035	$ 44,665
Sales Revenue [Member]
Sales revenue	7,516	0	14,035	0
License [Member]
Sales revenue	0	9,116	0	44,665
Diagnostics Segment [Member] | License [Member]
Sales revenue		9,116		44,665
Diagnostics Segment [Member] | Europe [Member] | Sales Revenue [Member]
Sales revenue	7,516	0	14,035	0
Diagnostics Segment [Member] | Europe [Member] | License [Member]
Sales revenue	$ 0	$ 9,116	$ 0	$ 44,665

Note 3 - Revenue From Contrac_5

Note 3 - Revenue From Contracts With Customers - Changes in Contract Liabilities (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Total deferred revenue related to contracts with customers, beginning of period	$ 700,000	$ 700,000	$ 700,000	$ 700,000
Deferred revenue related to milestones achieved	0	0	100,000	0
Deferred revenue related to milestones achieved, written off due to contract renegotiations	0	0	(100,000)	0
Total deferred revenue related to contracts with customers, end of period	$ 700,000	$ 700,000	$ 700,000	$ 700,000

Note 4 - Stock-based Compensa_3

Note 4 - Stock-based Compensation (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Share-Based Payment Arrangement, Expense	$ 41,052	$ 108,157	$ 266,456	$ 371,635
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)			$ 0.65
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum			93.94%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate			2.34%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term (Year)			6 years 3 months
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total	$ 106,476		$ 106,476
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)			1 year 6 months

Note 4 - Stock-based Compensa_4

Note 4 - Stock-based Compensation - Summary of Stock Option Activity (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Outstanding at beginning of period (in shares)	919,790
Outstanding at beginning of period, weighted average exercise price (in dollars per share)	$ 5.67
Outstanding, weighted average remaining contractual life (Year)	5 years 8 months 12 days	6 years 6 months
Granted (in shares)	12,500
Granted, weighted average exercise price (in dollars per share)	$ 0.83
Cancelled/Forfeited (in shares)	(152,455)
Cancelled/Forfeited, weighted average exercise price (in dollars per share)	$ 2.38
Expired (in shares)	(73,755)
Expired, weighted average exercise price (in dollars per share)	$ 22.96
Outstanding at end of period (in shares)	706,080	919,790
Outstanding at end of period, weighted average exercise price (in dollars per share)	$ 4.48	$ 5.67
Exercisable at end of period (in shares)	532,749
Exercisable at end of period, weighted average exercise price (in dollars per share)	$ 5.45
Exercisable, weighted average remaining contractual life (Year)	4 years 8 months 12 days

Note 4 - Stock-based Compensa_5

Note 4 - Stock-based Compensation - Summary of Unvested Restricted Stock (Details) - Restricted Stock [Member]	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Unvested at beginning of period (in shares) | shares	95,000
Unvested at beginning of period, weighted average grant-date fair value (in dollars per share) | $ / shares	$ 1.40
Vested (in shares) | shares	(5,000)
Vested, weighted average grant-date fair value (in dollars per share) | $ / shares	$ 1.96
Unvested at end of period (in shares) | shares	90,000
Unvested at end of period, weighted average grant-date fair value (in dollars per share) | $ / shares	$ 1.37

Note 5 - Loss Per Share (Detail

Note 5 - Loss Per Share (Details Textual) - shares	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Stock Options and Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	24,288,310	1,685,104
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	90,000	38,333

Note 6 - Inventory (Details Tex

Note 6 - Inventory (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Inventory Write-down	$ 133,006		$ 133,006	$ 0
Finished Goods [Member]
Inventory, Allocated to Research and Development Expense	$ 45,696	$ 0	$ 45,696	$ 10,404

Note 6 - Inventory - Net Invent

Note 6 - Inventory - Net Inventory (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Materials	$ 193,806	$ 50,000
Finished goods	133,006	101,155
Reserve for obsolete finished goods	(133,006)	0
Total inventory, net	$ 193,806	$ 151,155

Note 7 - Accounts Payable, Ac_2

Note 7 - Accounts Payable, Accrued Liabilities and Other (Details Textual) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
UCSD [Member]
License Agreement Fees	$ 1,400,000
Account Payable [Member] | UCSD [Member]
License Agreement Fees	104,000
Accrued Liabilities and Other [Member] | UCSD [Member]
License Agreement Fees	1,300,000
Director Fees [Member] | Account Payable [Member]
Due to Related Parties, Current, Total	226,682	$ 57,099
Director Fees [Member] | Accrued Liabilities and Other [Member]
Due to Related Parties, Current, Total	$ 797,672	$ 1,194,719

Note 8 - Notes Payable (Details

Note 8 - Notes Payable (Details Textual) - USD ($)			1 Months Ended		3 Months Ended		9 Months Ended
	Jul. 01, 2022	Apr. 10, 2022	Nov. 30, 2021	Nov. 30, 2020	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Difference Betweent Value of Conversion Stocks		$ 821,250
Interest Expense, Debt, Total					$ 100,696	$ 0	$ 188,004	$ 3,883
Notes Payable, Current, Total					0		0		$ 453,427
Notes Payable Issued for Prepayment of Insurance Premiums [Member] | FIF [Member]
Debt Instrument, Face Amount			$ 565,760	$ 442,041
Debt Instrument, Interest Rate, Stated Percentage			4.36%	3.50%
Debt Instrument, Term (Year)			5 months	7 months
Interest Expense, Debt, Total					0	$ 0	4,126	$ 3,883
Debt Instrument, Periodic Payment, Total			$ 114,388	$ 63,888
Notes Payable, Current, Total					0		0
Series E Preferred Stock Exchanged for Sereis F and G Preferred Stock [Member]
Conversion of Stock, Shares Converted (in shares)		50,000
Series E Preferred Stock Exchanged for Sereis F Preferred Stock [Member]
Conversion of Stock, Shares Issued (in shares)		1,740
Series E Preferred Stock Exchanged for Sereis G Preferred Stock [Member]
Conversion of Stock, Shares Issued (in shares)		3,260
Bridge Loan [Member]
Debt Instrument, Face Amount		$ 2,500,000
Proceeds from Issuance of Long-Term Debt, Total	$ 1,000,000	$ 1,500,000
Debt Instrument, Interest Rate, Stated Percentage		8%
Debt Instrument, Term (Year)		2 years
Debt Instrument, Unamortized Discount, Total		$ 835,876			708,999		708,999
Debt Issuance Costs, Net, Total		$ 14,626
Interest Expense, Debt, Total					100,696		183,878
Long-Term Debt, Total					$ 2,500,000		$ 2,500,000

Note 9 - Leases (Details Textua

Note 9 - Leases (Details Textual)	1 Months Ended	3 Months Ended			9 Months Ended
	Jun. 30, 2017 USD ($)	Sep. 30, 2022 USD ($) ft²	Mar. 31, 2022 USD ($)	Sep. 30, 2021 USD ($) ft²	Sep. 30, 2022 USD ($) ft²	Sep. 30, 2021 USD ($) ft²
Operating Lease, Expense (Reversal)		$ (29,681)
Operating Lease, Expense				$ 41,653	$ 43,493	$ 131,399
Operating Lease, Payments					$ 281,668	$ 250,376
Office Space at 4995 Bradenton Avenue, Dublin Ohio [Member]
Area of Real Estate Property (Square Foot) | ft²				5,000		5,000
Operating Lease, Monthly Base Rent			$ 3,012
Office Space at 5600 Blazer Parkway, Dublin, Ohio [Member]
Area of Real Estate Property (Square Foot) | ft²		25,000			25,000
Operating Lease, Monthly Base Rent	$ 39,124				$ 28,149
Lessee, Operating Lease, Renewal Term (Year)		5 years			5 years
Office Equipment [Member]
Operating Lease, Monthly Base Rent					$ 136
Vehicle Lease [Member]
Operating Lease, Monthly Base Rent					$ 287

Note 9 - Leases - Maturity of L

Note 9 - Leases - Maturity of Lease Liabilities (Details)	Sep. 30, 2022 USD ($)
2022 (remaining)	$ 9,443
2023	19,699
2024	1,355
Total undiscounted operating lease payments	30,497
Less imputed interest	1,461
Present value of operating lease liabilities	$ 29,036

Note 9 - Leases - Balance Sheet

Note 9 - Leases - Balance Sheet Classification (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Current lease liabilities	$ 27,346	$ 275,718
Noncurrent lease liabilities	1,690	$ 20,288
Present value of operating lease liabilities	29,036
Other Current Liabilities [Member]
Current lease liabilities	27,346
Other Noncurrent Liabilities [Member]
Noncurrent lease liabilities	$ 1,690

Note 9 - Leases - Other Informa

Note 9 - Leases - Other Information (Details)	Sep. 30, 2022
Weighted-average remaining lease term for operating leases (in years) (Year)	10 months 24 days
Weighted-average discount rate for operating leases	10.70%

Note 10 - Commitments and Con_2

Note 10 - Commitments and Contingencies (Details Textual) - USD ($)

1 Months Ended

3 Months Ended

19 Months Ended

Aug. 30, 2022

Dec. 09, 2021

Nov. 21, 2021

May 27, 2021

Mar. 16, 2021

Nov. 27, 2019

Aug. 14, 2018

Apr. 09, 2018

Nov. 02, 2017

Nov. 30, 2018

Sep. 30, 2022

Jun. 30, 2021

Mar. 31, 2022

Oct. 11, 2022

Jun. 30, 2022

Jan. 31, 2022

Dec. 31, 2021

Sep. 30, 2021

Mar. 31, 2021

Dec. 31, 2020

Aug. 31, 2018

Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance

$ (4,667,116)

$ 6,436,170

$ (2,109,442)

$ (4,240,647)

$ 624,743

$ 4,133,994

$ 5,008,882

$ 2,046,907

Common Stock [Member]

Stock Issued During Period, Shares, New Issues (in shares)

70,500

0

Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance

$ 223,148

$ 221,142

221,354

$ 221,361

$ 221,277

$ 221,160

$ 219,703

$ 218,146

MT [Member]

Ownership Percentage

60%

Former Chief Executive Officer and President [Member]

Common Stock Shares Provided by Agreement (in shares)

1,175,000

Common Stock Shares Provided by Agreement, Escrow Period (Month)

18 months

Former Chief Executive Officer and President [Member] | Common Stock [Member]

Stock Issued During Period, Shares, New Issues (in shares)

925,000

Stock Issued During Period, Shares, New Issues Placed in Escrow (in shares)

250,000

Former Chief Executive Officer and President [Member] | MT [Member] | Common Stock [Member] | Dr. Michael Goldberg [Member]

Ownership Percentage

5%

CRG Loan Agreement, Texas Case [Member]

Litigation Settlement, Attorneys’ Fees

$ 2,800,000

Litigation Settlement, Amount Awarded to Other Party

$ 2,600,000

Loss Contingency Accrual, Ending Balance

$ 3,300,000

CRG Loan Agreement, Texas Case [Member] | Subsequent Event [Member]

Loss Contingencies, Interest Rate

18%

CRG Loan Agreement, Texas Case [Member] | CRG [Member] | Term Loan Agreement [Member]

Overpayment of Debt

$ 4,200,000

Ohio Court of Common Pleas [Member]

Litigation Settlement, Amount Awarded from Other Party

$ 4,300,000

Litigation Settlement, Reversal of Amount Awarded from Other Party

$ 4,300,000

Platinum-Montaur Life Sciences LLC Litigation [Member] | Pending Litigation [Member]

Loss Contingency, Damages Sought, Value

$ 1,900,000

New York Litigation Involving Former CEO and President [Member] | Judicial Ruling [Member]

Litigation Settlement, Amount Can Be Awarded to Other Party for Indemnification for Attorneys’ Fees

$ 14,955

Litigation Settlement, Amount Can Be Advanced to Other Party for Attorneys’ Fees Subject to Repayment

$ 1,237.50

Litigation Settlement, Advancement for Attorney's Fees and Disbursements

$ 143,172.55

Delaware Litigation Involving Former CEO and President [Member]

Litigation Settlement, Amount Awarded from Other Party

$ 66,796.33

CRG [Member]

Draws on Letter of Credit

$ 7,153,000

Note 11 - Equity (Details Textu

Note 11 - Equity (Details Textual)							3 Months Ended				9 Months Ended
	Sep. 09, 2022	Aug. 30, 2022 USD ($) $ / shares shares	Aug. 03, 2022 $ / shares shares	Jul. 01, 2022 USD ($)	Apr. 10, 2022 USD ($) shares	Apr. 07, 2022 shares	Sep. 30, 2022 USD ($) shares	Mar. 31, 2022 USD ($) shares	Jun. 30, 2021 USD ($) shares	Mar. 31, 2021 USD ($) shares	Sep. 30, 2022 USD ($) shares	Sep. 30, 2021 USD ($) shares	Jan. 31, 2022 USD ($) shares	Dec. 31, 2021 USD ($)
Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance							$ 292,517				$ 292,517			$ 731,299
Additional Paid in Capital, Total							$ 379,337,227				$ 379,337,227			370,459,705
Operating Loss Carryforwards														164,000,000
Share Purchase Right, Ownership Percentage Threshold						4.99%
Share Purchase Right, Ownership Percentage Trigger						0.50%
Share Purchase Right, Discount Percentage						50%
Rights Offering, Shares Authorized (in shares) | shares			35,000
Shares Issued, Price Per Share (in dollars per share) | $ / shares			$ 1,000
Units Issued During Period, Units, New Issues (in shares) | shares		10,423
Proceeds from Issuance or Sale of Equity, Total		$ 6,173,000
Class of Warrant or Right, Outstanding (in shares) | shares							23,582,230				23,582,230
Units Issued During Period, Value, New Issues		10,423,000
Stock Issued During Period, Value, New Issues							$ 19,740		$ 1,800,000
Payments to Fund Clinical Research Trial		$ 963,270
Stock Issued During Period, Shares, Employee Benefit Plan (in shares) | shares											53,238	30,018
Stock Issued During Period, Value, Employee Benefit Plan								$ 44,720		$ 76,846	$ 44,720	$ 76,846
Issuance of Stock to Defined Contribution Plan for Employer Matching Contribution											44,720	$ 76,846
LTIP [Member]
Stock Issued During Period, Value, New Issues											$ 19,740
Incentive Plan, Milestone, Percent, Step of Total Stock Award Payout	5%
Incentive Plan, Milestone, Percent, Regulatory Milestones	90%
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage	100%
Incentive Plan, Percent, Milestones Paid											5%
Stock Issued During Period, Shares, New Issues (in shares) | shares											70,500
Common Stock [Member]
Stock Issued During Period, Value, New Issues							$ 71		$ 0	$ 0
Stock Issued During Period, Shares, Employee Benefit Plan (in shares) | shares								53,238		30,018
Stock Issued During Period, Value, Employee Benefit Plan								$ 53		$ 30
Stock Issued During Period, Shares, Issued for Employee Bonuses (in shares) | shares							28,150	16,632
Stock Issued During Period, Shares, New Issues (in shares) | shares							70,500		0
Employees [Member] | Common Stock [Member]
Stock Issued During Period, Shares, Issued for Employee Bonuses (in shares) | shares											44,782
Issuance of Stock to Defined Contribution Plan for Employer Matching Contribution											$ 24,847
John K. Scott, Jr. [Member]
Maximum Number of Units Purchasable (in shares) | shares		2,400
Unit Warrants [Member]
Class of Warrant or Right, Outstanding (in shares) | shares		1
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares		2,222
Class of Warrant or Right, Purchase Price of Stock (in dollars per share) | $ / shares		$ 0.45
Class of Warrants or Rights, Warrant Proceeds if Exercised		$ 11,600,000
Warrants and Rights Outstanding		$ 4,144,185
Unit Warrants [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input		0.8925
Unit Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input		0.0327
Unit Warrants [Member] | Measurement Input, Expected Dividend Payment [Member]
Warrants and Rights Outstanding, Measurement Input		0
Series E Preferred Stock Exchanged for Sereis F and G Preferred Stock [Member]
Conversion of Stock, Shares Converted (in shares) | shares					50,000
Series E Preferred Stock Exchanged for Sereis F Preferred Stock [Member]
Conversion of Stock, Shares Issued (in shares) | shares					1,740
Series E Preferred Stock Exchanged for Sereis G Preferred Stock [Member]
Conversion of Stock, Shares Issued (in shares) | shares					3,260
Units Sold in Exchange for Series D Preferred Stock [Member]
Units Issued During Period, Units, New Issues (in shares) | shares		4,250
Convertible Preferred Stock, Fair Value											2,212,114
Convertible Preferred Stock, Shares Issued Upon Conversion, Fair Value											4,250,000
Dividends, Preferred Stock, Total											$ 2,037,886
Bridge Loan [Member]
Debt Instrument, Face Amount					$ 2,500,000
Proceeds from Issuance of Long-Term Debt, Total				$ 1,000,000	$ 1,500,000
Debt Instrument, Interest Rate, Stated Percentage					8%
Debt Instrument, Term (Year)					2 years
MT [Member]
Ownership Percentage													60%
Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance														$ 731,299
MT Preferred Stock [Member]
Preferred Stock, Stock Returned (in shares) | shares													6
Additional Paid in Capital, Total													$ 438,778
Series H Preferred Stock [Member]
Share Purchase Right, Shares Issuable Per Each Right (in shares) | shares						1,000
Series I Preferred Stock [Member]
Convertible Preferred Stock, Shares Issued upon Conversion (in shares) | shares		2,222
Stock Issued During Period, Value, New Issues		$ 6,278,815					$ 5,209,735
Series I Preferred Stock [Member] | Common Stock [Member]
Stock Issued During Period, Value, New Issues							$ 0
Stock Issued During Period, Shares, New Issues (in shares) | shares							0

Note 12 - Stock Warrants (Detai

Note 12 - Stock Warrants (Details Textual) - $ / shares	Mar. 03, 2022	Sep. 30, 2022
Class of Warrant or Right, Outstanding (in shares)		23,582,230
Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 0.20
Warrants and Rights Outstanding, Term (Year)		8 months 12 days
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 49.80
Warrants and Rights Outstanding, Term (Year)		12 years 10 months 24 days
Weighted Average [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 0.53
Series NN Warrants [Member]
Class of Warrant or Right, Expired in Period (in shares)	550,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 30
Series PP Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 0.50
Class of Warrant or Right, Outstanding (in shares)		23,159,906
Warrants and Rights Outstanding, Term (Year)		5 years

Note 13 - Income Taxes (Details

Note 13 - Income Taxes (Details Textual) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Unrecognized Tax Benefits, Ending Balance	$ 0	$ 0
Operating Loss Carryforwards		$ 164,000
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
Operating Loss Carryforwards	164,100
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member]
Tax Credit Carryforward, Amount	9,100
State and Local Jurisdiction [Member]
Operating Loss Carryforwards	$ 20,100

Note 14 - Segments (Details Tex

Note 14 - Segments (Details Textual)		3 Months Ended		9 Months Ended
		Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)
Revenues, Total		$ 7,516	$ 96,382	$ 65,042	$ 481,165
Number of Primary Types of Products Sold		2		2
Depreciation, Depletion and Amortization, Nonproduction, Total	[1]	$ 24,703	$ 18,066	$ 69,352	$ 55,672
Intersegment Eliminations [Member]
Revenues, Total				$ 0
[1]Depreciation and amortization are reflected in selling, general and administrative expenses ($24,703 and $18,066 for the three-month periods ended September 30, 2022 and 2021, and $69,352 and $55,672 for the nine-month periods ended September 30, 2022 and 2021, respectively).

Note 14 - Segments - Segment In

Note 14 - Segments - Segment Information (Details) - USD ($)		3 Months Ended						9 Months Ended
		Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Revenue from Contract with Customer, Including Assessed Tax		$ 7,516			$ 9,116			$ 14,035	$ 44,665
Grant and other revenue		0			87,266			51,007	436,500
Revenues, Total		7,516			96,382			65,042	481,165
Cost of revenue, excluding depreciation and amortization		1,432						1,905
Inventory Write-down		133,006						133,006	0
Research and development expenses		1,186,419			1,048,786			4,079,661	3,769,596
Selling, general and administrative expenses, excluding depreciation and amortization	[1]	3,612,747			1,451,309			6,633,793	5,077,058
Depreciation, Depletion and Amortization, Nonproduction, Total	[2]	24,703			18,066			69,352	55,672
Income (loss) from operations	[3]	(4,950,791)			(2,421,779)			(10,852,675)	(8,421,161)
Other expense, net	[4]	(757,034)			(14)			(841,853)	358,436
Net loss		(5,707,825)	$ (2,999,459)	$ (2,987,245)	(2,437,836)	$ (2,674,040)	$ (2,966,892)	(11,694,528)	(8,078,768)
Total assets, net of depreciation and amortization		6,258,432						6,258,432		$ 6,644,833
Capital expenditures		14,429			18,042			63,086	20,749
Income tax expense		0			(16,043)			0	(16,043)
UNITED STATES
Total assets, net of depreciation and amortization		5,979,692			8,742,603			5,979,692	8,742,603
Non-US [Member]
Total assets, net of depreciation and amortization		278,740			216,943			278,740	216,943
Diagnostics Segment [Member]
Grant and other revenue		0			87,266			51,007	436,500
Revenues, Total		7,516			96,382			65,042	481,165
Cost of revenue, excluding depreciation and amortization		1,432						1,905
Inventory Write-down		133,006						133,006
Research and development expenses		1,073,950			906,677			3,700,528	3,359,190
Selling, general and administrative expenses, excluding depreciation and amortization	[1]	0			0			0	0
Depreciation, Depletion and Amortization, Nonproduction, Total	[2]	8,532			6,040			20,613	18,121
Income (loss) from operations	[3]	(1,209,404)			(816,335)			(3,791,010)	(2,896,146)
Other expense, net	[4]	0			0			0	0
Net loss		(1,209,404)			(822,098)			(3,791,010)	(2,901,909)
Capital expenditures		14,429			0			54,650	0
Income tax expense					(5,763)				(5,763)
Diagnostics Segment [Member] | UNITED STATES
Total assets, net of depreciation and amortization		50,000			185,205			50,000	185,205
Diagnostics Segment [Member] | Non-US [Member]
Total assets, net of depreciation and amortization		271,939			216,353			271,939	216,353
Therapeutics Segment [Member]
Grant and other revenue		0			0			0	0
Revenues, Total		0			0			0	0
Cost of revenue, excluding depreciation and amortization		0						0
Inventory Write-down		0						0
Research and development expenses		112,469			142,109			379,133	410,406
Selling, general and administrative expenses, excluding depreciation and amortization	[1]	745			744			3,746	3,623
Depreciation, Depletion and Amortization, Nonproduction, Total	[2]	0			0			0	0
Income (loss) from operations	[3]	(113,214)			(142,853)			(382,879)	(414,029)
Other expense, net	[4]	0			0			0	0
Net loss		(113,214)			(143,677)			(382,879)	(414,853)
Capital expenditures		0			0			0	0
Income tax expense					(824)				(824)
Therapeutics Segment [Member] | UNITED STATES
Total assets, net of depreciation and amortization		0			0			0	0
Therapeutics Segment [Member] | Non-US [Member]
Total assets, net of depreciation and amortization		0			0			0	0
Corporate Segment [Member]
Grant and other revenue		0			0			0	0
Revenues, Total		0			0			0	0
Cost of revenue, excluding depreciation and amortization		0						0
Inventory Write-down		0						0
Research and development expenses		0			0			0	0
Selling, general and administrative expenses, excluding depreciation and amortization	[1]	3,612,002			1,450,565			6,630,047	5,073,435
Depreciation, Depletion and Amortization, Nonproduction, Total	[2]	16,171			12,026			48,739	37,551
Income (loss) from operations	[3]	(3,628,173)			(1,462,591)			(6,678,786)	(5,110,986)
Other expense, net	[4]	(757,034)			(14)			(841,853)	358,436
Net loss		(4,385,207)			(1,472,062)			(7,520,639)	(4,762,007)
Capital expenditures		0			18,042			8,436	20,749
Income tax expense					(9,457)				(9,457)
Corporate Segment [Member] | UNITED STATES
Total assets, net of depreciation and amortization		5,929,692			8,557,398			5,929,692	8,557,398
Corporate Segment [Member] | Non-US [Member]
Total assets, net of depreciation and amortization		6,801			590			6,801	590
License [Member]
Revenue from Contract with Customer, Including Assessed Tax		0			9,116			0	44,665
License [Member] | Diagnostics Segment [Member]
Revenue from Contract with Customer, Including Assessed Tax					9,116				44,665
License [Member] | Therapeutics Segment [Member]
Revenue from Contract with Customer, Including Assessed Tax					0				0
License [Member] | Corporate Segment [Member]
Revenue from Contract with Customer, Including Assessed Tax					0				0
Sales Revenue [Member]
Revenue from Contract with Customer, Including Assessed Tax		7,516			$ 0			14,035	$ 0
Sales Revenue [Member] | UNITED STATES
Revenue from Contract with Customer, Including Assessed Tax		0						0
Sales Revenue [Member] | Non-US [Member]
Revenue from Contract with Customer, Including Assessed Tax		7,516						14,035
Sales Revenue [Member] | Diagnostics Segment [Member] | UNITED STATES
Revenue from Contract with Customer, Including Assessed Tax		0						0
Sales Revenue [Member] | Diagnostics Segment [Member] | Non-US [Member]
Revenue from Contract with Customer, Including Assessed Tax		7,516						14,035
Sales Revenue [Member] | Therapeutics Segment [Member] | UNITED STATES
Revenue from Contract with Customer, Including Assessed Tax		0						0
Sales Revenue [Member] | Therapeutics Segment [Member] | Non-US [Member]
Revenue from Contract with Customer, Including Assessed Tax		0						0
Sales Revenue [Member] | Corporate Segment [Member] | UNITED STATES
Revenue from Contract with Customer, Including Assessed Tax		0						0
Sales Revenue [Member] | Corporate Segment [Member] | Non-US [Member]
Revenue from Contract with Customer, Including Assessed Tax		$ 0						$ 0
[1]General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not currently allocated to our individual reportable segments, other than those expenses directly incurred by Navidea Europe, Navidea UK and MT.[2]Depreciation and amortization are reflected in selling, general and administrative expenses ($24,703 and $18,066 for the three-month periods ended September 30, 2022 and 2021, and $69,352 and $55,672 for the nine-month periods ended September 30, 2022 and 2021, respectively).[3]Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments, other than those expenses directly incurred by Navidea Europe, Navidea UK and MT.[4]Amounts consist primarily of interest income and interest expense, which are not currently allocated to our individual reportable segments.

Note 15 - Supplemental Disclo_2

Note 15 - Supplemental Disclosure for Statements of Cash Flows (Details Textual) - USD ($)	3 Months Ended					9 Months Ended
	Sep. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021
Interest Paid, Excluding Capitalized Interest, Operating Activities						$ 81,126	$ 6,960
Proceeds from Issuance of Preferred Stock and Preference Stock						$ 6,173,000	$ 12,682,700
Stock Issued During Period, Shares, Employee Benefit Plan (in shares)						53,238	30,018
Stock Issued During Period, Value, Employee Benefit Plan		$ 44,720			$ 76,846	$ 44,720	$ 76,846
Issuance of Stock to Defined Contribution Plan for Employer Matching Contribution						$ 44,720	76,846
Stock Issued During Period, Value, New Issues	$ 19,740			$ 1,800,000
LTIP [Member]
Stock Issued During Period, Shares, New Issues (in shares)						70,500
Stock Issued During Period, Value, New Issues						$ 19,740
Common Stock [Member]
Stock Issued During Period, Shares, Employee Benefit Plan (in shares)		53,238			30,018
Stock Issued During Period, Value, Employee Benefit Plan		$ 53			$ 30
Stock Issued During Period, Shares, Issued for Employee Bonuses (in shares)	28,150	16,632
Stock Issued During Period, Shares, New Issues (in shares)	70,500			0
Stock Issued During Period, Value, New Issues	$ 71			$ 0	0
Employees [Member] | Common Stock [Member]
Stock Issued During Period, Shares, Issued for Employee Bonuses (in shares)						44,782
Issuance of Stock to Defined Contribution Plan for Employer Matching Contribution						$ 24,847
Series D Preferred Stock [Member]
Stock Issued During Period, Value, New Issues			$ 0		$ 250,001
Series D Preferred Stock [Member] | Common Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)			0		0
Stock Issued During Period, Value, New Issues			$ 0
Series D Preferred Stock [Member] | Keystone Capital Partners, LLC [Member]
Proceeds from Issuance of Preferred Stock and Preference Stock							$ 2,925,000